F
Fiona J. Gilbert
Researcher at University of Cambridge
Publications - 293
Citations - 15238
Fiona J. Gilbert is an academic researcher from University of Cambridge. The author has contributed to research in topics: Breast cancer & Mammography. The author has an hindex of 53, co-authored 274 publications receiving 12116 citations. Previous affiliations of Fiona J. Gilbert include Aberdeen Royal Infirmary & University of Aberdeen.
Papers
More filters
Journal ArticleDOI
International evaluation of an AI system for breast cancer screening.
Scott Mayer McKinney,Marcin Sieniek,Varun Godbole,Jonathan Godwin,Natasha Antropova,Hutan Ashrafian,Trevor Back,Mary Chesus,Greg C. Corrado,Ara Darzi,Mozziyar Etemadi,Florencia Garcia-Vicente,Fiona J. Gilbert,Mark D. Halling-Brown,Demis Hassabis,Sunny Jansen,Alan Karthikesalingam,Christopher Kelly,Dominic King,Joseph R. Ledsam,David S. Melnick,Hormuz Mostofi,Lily Peng,Joshua J. Reicher,Bernardino Romera-Paredes,Richard Sidebottom,Mustafa Suleyman,Daniel Tse,Kenneth C. Young,Jeffrey De Fauw,Shravya Shetty +30 more
TL;DR: A robust assessment of the AI system paves the way for clinical trials to improve the accuracy and efficiency of breast cancer screening and using a combination of AI and human inputs could help to improve screening efficiency.
Journal ArticleDOI
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
Martin O. Leach,Caroline Boggis,Adrian K. Dixon,Douglas F. Easton,Rosalind A. Eeles,D G R Evans,Fiona J. Gilbert,I Griebsch,Rebecca Hoff,Preminda Kessar,Sunil R. Lakhani,Sue Moss,Ashutosh Nerurkar,Anwar R. Padhani,Linda Pointon,Deborah J. Thompson,Ruth Warren +16 more
TL;DR: In this paper, the authors compared contrast enhanced magnetic resonance imaging (CE MRI) with mammography for screening of women genetically predisposed to breast cancer and found that CE MRI is more sensitive than mammography.
Journal ArticleDOI
Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group.
Francesco Sardanelli,Carla Boetes,Bettina Borisch,Thomas Decker,Massimo Federico,Fiona J. Gilbert,Thomas H. Helbich,S H Heywang-Köbrunner,Werner A. Kaiser,Michael J. Kerin,Robert E. Mansel,Lorenza Marotti,L. Martincich,L. Mauriac,Hanne Meijers-Heijboer,Roberto Orecchia,Pietro Panizza,Antonio Ponti,Arnie Purushotham,Peter Regitnig,Marco Rosselli Del Turco,Fabienne Thibault,Robin Wilson +22 more
TL;DR: The working group strongly suggests that all breast cancer specialists cooperate for an optimal clinical use of this emerging technology and for future research, focusing on patient outcome as primary end-point.
Journal ArticleDOI
Imaging biomarker roadmap for cancer studies.
James P B O'Connor,Eric O. Aboagye,Judith E. Adams,Hugo J.W.L. Aerts,Hugo J.W.L. Aerts,Sally F. Barrington,Ambros J. Beer,Ronald Boellaard,Sarah E. Bohndiek,J. Michael Brady,Gina Brown,David L. Buckley,Thomas L. Chenevert,Laurence P. Clarke,Sandra Collette,Gary Cook,Nandita M. deSouza,John Dickson,Caroline Dive,Jeffrey L. Evelhoch,Corinne Faivre-Finn,Ferdia A. Gallagher,Fiona J. Gilbert,Robert J. Gillies,Vicky Goh,John R. Griffiths,Ashley M. Groves,Steve Halligan,Adrian L. Harris,David J. Hawkes,Otto S. Hoekstra,Erich P. Huang,Brian Hutton,Edward F. Jackson,Gordon C Jayson,Andrew J. I. Jones,Dow-Mu Koh,Denis Lacombe,Philippe Lambin,Nathalie Lassau,Martin O. Leach,Ting-Yim Lee,Edward Leen,Jason S. Lewis,Yan Liu,Mark F. Lythgoe,Prakash Manoharan,Ross J. Maxwell,Kenneth A. Miles,Bruno Morgan,Steve Morris,Tony Ng,Anwar R. Padhani,Geoff J M Parker,Mike Partridge,Arvind P. Pathak,Arvind P. Pathak,Andrew C. Peet,Shonit Punwani,Andrew R. Reynolds,Simon P. Robinson,Lalitha K. Shankar,Ricky A. Sharma,Dmitry Soloviev,Sigrid Stroobants,Daniel C. Sullivan,Stuart A. Taylor,Paul S. Tofts,Gillian M. Tozer,Marcel van Herk,Simon Walker-Samuel,James Wason,Kaye J. Williams,Paul Workman,Thomas E. Yankeelov,Kevin M. Brindle,Lisa M. McShane,Alan Jackson,John C. Waterton +78 more
TL;DR: Experts assembled to review, debate and summarize the challenges of IB validation and qualification produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical validation, biological/clinical validation and assessment of cost-effectiveness.
Journal ArticleDOI
Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel
Ian C. Smith,Steven D. Heys,Andrew W. Hutcheon,Iain D. Miller,S. Payne,Fiona J. Gilbert,A K Ah-See,Oleg Eremin,Leslie G. Walker,T. K. Sarkar,S. Peter Eggleton,Keith N. Ogston +11 more
TL;DR: NA DOC resulted in substantial improvement in responses to DOC, and patients with breast cancer initially failing to respond to anthracycline-based NA chemotherapy (CT) had residual tumor within axillary lymph nodes.